« Back
Home /
ABT-263

ABT-263

Item no.	M1637-25mg
Manufacturer	AbMole
CASRN	923564-51-6
Amount	25mg
Category	Oncology Inhibitors & Compound Libraries Small Molecules By Organ Lung Cancer Heart & Blood Cancer
Type	Inhibitors
Specific against	other
Purity	0,9979
Citations	Efficient elimination of cancer cells by deoxyglucose-ABT-263/737 combination therapy. Yamaguchi, et al . PLoS One. 2011,6(9):e24102. PMID: 21949692 . Navitoclax (ABT-263) accelerates apoptosis during drug-induced mitotic arrest by antagonizing Bcl-xL. Shi, et al . Cancer Res. 2011 Jul 1,71(13):4518-26. PMID: 21546570 . Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors. Gandhi, et al . J Clin Oncol. 2011 Mar 1,29(7):909-16. PMID: 21282543 . Identification of expression signatures predictive of sensitivity to the Bcl-2 family member inhibitor ABT-263 in small cell lung carcinoma and leukemia/lymphoma cell lines. Tahir, et al . Mol Cancer Ther. 2010 Mar,9(3):545-57. PMID: 20179162 .
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	Navitoclax
Similar products	ABT-263, Navitoclax
Available
Target Information	Bcl-2
Molecular Weight	974, 61
Solubility	DMSO ≥100 mg/mL
Bioactivity information	ABT-263 (Navitoclax) is a potent, orally bioavailable inhibitor of the antiapoptotic Bcl-2 family members Bcl-2, Bcl-x (L), and Bcl-w.

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

M1637-25mg-safety-datasheet.pdf